Olokizumab

DB13127

biotech investigational

Deskripsi

Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. IL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman disease, and cytokine release syndrome. Targeting IL-6 function can be achieved directly, or through interrupting the IL-6 receptor or gp130 receptor axes.A241185, A241175 Olokizumab is a humanized anti-IL-6 IgG4? antibody that directly blocks gp130 binding at IL-6 Site 3.A241045

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) When administered either intravenously or subcutaneously to healthy volunteers, olokizumab has a half-life of 22.7-47.4 days.[A241195]
Volume Distribusi When administered either intravenously or subcutaneously to healthy volunteers, olokizumab has a volume of distribution between 5.59-9.71 L.[A241195]
Klirens (Clearance) When administered either intravenously or subcutaneously to healthy volunteers, olokizumab has a clearance of 0.116-0.204 L/day.[A241195]

Absorpsi

Olokizumab administered as a single escalating subcutaneous dose in healthy volunteers had a Cmax between 2.99 ± 0.271 and 22.3 ± 4.48 ?g/mL for doses between 0.3 and 3.0 mg/kg. The maximum concentration was achieved at a median of between 120 and 336 hours. The corresponding AUC0-t and AUC0-? ranges were 2,704 ± 886 to 24,723 ± 2,145 and 2,988 ± 1,124 to 30,444 ± 4,913 ?g\*h/mL, respectively. The bioavailability ranged between 85.7-92.5%.A241195 When administered as a single escalating intravenous dose between 0.001-10.0 mg/kg, the Cmax varied between 0.242 ± 0.0262 and 207 ± 14.7 ?g/mL and was typically achieved within a median time of 2-4 hours. The corresponding AUC0-t and AUC0-? ranges were 101 ± 46.3 to 120,294 ± 16,882 and 303 ± 111 to 159,072 ± 50,801 ?g\*h/mL, respectively.A241195

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Olokizumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Olokizumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Olokizumab.
Estrone Estrone may increase the thrombogenic activities of Olokizumab.
Estradiol Estradiol may increase the thrombogenic activities of Olokizumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Olokizumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Olokizumab.
Mestranol Mestranol may increase the thrombogenic activities of Olokizumab.
Estriol Estriol may increase the thrombogenic activities of Olokizumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Olokizumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Olokizumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Olokizumab.
Tibolone Tibolone may increase the thrombogenic activities of Olokizumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Olokizumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Olokizumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Olokizumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Olokizumab.
Zeranol Zeranol may increase the thrombogenic activities of Olokizumab.
Equol Equol may increase the thrombogenic activities of Olokizumab.
Promestriene Promestriene may increase the thrombogenic activities of Olokizumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Olokizumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Olokizumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Olokizumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Olokizumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Olokizumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Olokizumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Olokizumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Olokizumab.
Formononetin Formononetin may increase the thrombogenic activities of Olokizumab.
Estetrol Estetrol may increase the thrombogenic activities of Olokizumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Olokizumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Olokizumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Olokizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Olokizumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Olokizumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olokizumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Olokizumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Olokizumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Olokizumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Olokizumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Olokizumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Olokizumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Olokizumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olokizumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Olokizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olokizumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Olokizumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Olokizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olokizumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Olokizumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Olokizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Olokizumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olokizumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Olokizumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Olokizumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Olokizumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Olokizumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Olokizumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Olokizumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Olokizumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Olokizumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Olokizumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Olokizumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Olokizumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Olokizumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Olokizumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Olokizumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Olokizumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Olokizumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Olokizumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Olokizumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Olokizumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Olokizumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Olokizumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Olokizumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Olokizumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Olokizumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Olokizumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Olokizumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Olokizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Olokizumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Olokizumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Olokizumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Olokizumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Olokizumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Olokizumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Olokizumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Olokizumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Olokizumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Olokizumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Olokizumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Olokizumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Olokizumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Olokizumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Olokizumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Olokizumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Olokizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Olokizumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Olokizumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Olokizumab.

Target Protein

Interleukin-6 IL6

Referensi & Sumber

Artikel (PubMed)
  • PMID: 29725131
    Garbers C, Heink S, Korn T, Rose-John S: Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018 Jun;17(6):395-412. doi: 10.1038/nrd.2018.45. Epub 2018 May 4.
  • PMID: 24670876
    Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A: Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82. doi: 10.4161/mabs.28612. Epub 2014 Apr 2.
  • PMID: 33459118
    Kaplon H, Reichert JM: Antibodies to watch in 2021. MAbs. 2021 Jan-Dec;13(1):1860476. doi: 10.1080/19420862.2020.1860476.
  • PMID: 27129012
    Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, Jose J, Oliver R: Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014 Sep;3(5):388-95. doi: 10.1002/cpdd.121. Epub 2014 May 26.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul